Blauvelt, A. .; Sofen, H. .; Lambert, J. .; Merola, J. F. .; Lebwohl, M. .; Hoyt, K. .; Banerjee, S.; Scharnitz, T. .; Crowley, J. J. . Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data. J of Skin 2024, 8, s405.